A specific T cell receptor for egfr L858R gene mutation and its application

A cell receptor and specific technology, applied in the field of genetic engineering and tumor immunotherapy, can solve the problems of unverified therapeutic effect and lack of effective TCR, etc., and achieve good therapeutic effect and strong specificity

Inactive Publication Date: 2020-04-03
天津亨佳生物科技发展有限公司
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since the development of TCR-T is still in its infancy, effective TCRs for specific mutations and corresponding patient populations are still very scarce
At the same time, the effective patient population of TCR-T and the therapeutic effect of the new structure of TCR-T have yet to be verified

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A specific T cell receptor for egfr L858R gene mutation and its application
  • A specific T cell receptor for egfr L858R gene mutation and its application
  • A specific T cell receptor for egfr L858R gene mutation and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Embodiment 1 TCR lentivirus preparation

[0052] The coding sequences of TCR α chain and β chain were connected by furin cleavage site, SGSG linker and F2A sequence, the α chain and β chain genes were fully synthesized, and the TCR gene was cloned into lentiviral expression using restriction endonucleases EcoRI and BamHI In the vector pCDH (purchased from SBI), a recombinant plasmid capable of expressing the amino acid sequences of the TCRα chain and β chain variable regions shown in Sequences 6 and 8 was obtained.

[0053] Transform the recombinant plasmid into XL-10 competent cells, evenly spread it on the LB solid medium plate containing ampicillin, culture at 37°C for 12 hours, pick a single colony into the LB liquid medium containing ampicillin, and incubate at 37°C , 220 rpm / min shaking culture for 14-16h, extract the plasmid.

[0054] Packaging of recombinant plasmids: Take 293T cells in the logarithmic growth phase (purchased from the Basic Medical Cell Center ...

Embodiment 2

[0055] Example 2 Preparation of TCR-T cells and analysis of TCR expression in TCR-T cells by flow cytometry

[0056] Peripheral blood from healthy volunteers was collected, and human peripheral blood mononuclear cells (PBMC) were separated using a lymphocyte separation medium (Stemcell, 07861, USA). Dynabeads (Gibco, 11141D) and PBMC were mixed and incubated at room temperature for 20 minutes to separate activated T cells. Add 3 mL of X-Vivo 15 medium (Lonza, DL-201) to T cells, resuspend the mixture of cells and Dynabeads (Thermo, 11141D) with a pipette, and adjust the cell density to 0.5-1×10 6 cells / mL to obtain a cell suspension. Place the cell suspension at 37°C, 5% CO 2 After continuous culture in the incubator for 48 h, the cell density was adjusted to 1x10 6 individual / mL. Take out the lentivirus from the -80°C ultra-low temperature refrigerator, thaw it quickly in a 37°C water bath, add polybrene (Santa Cruz, sc-134220) to the prepared T cells to a final concentra...

Embodiment 3

[0057] The preparation of embodiment 3 target cells

[0058] The lentiviral expression vector pCDH-A1101 overexpressing the HLA-A*1101 molecule was constructed, transiently transfected into 293T cells, and the recombinant lentivirus was prepared. The method was the same as in Example 1. The T2 cell line was transduced with the virus, and the T2 cell line expressing HLA-A*1101 was constructed according to the method in Example 2. After labeling with an antibody against HLA molecules, FACS was used to detect the expression of HLA-A*1101 on the surface of T2 cells, as shown in Figure 2. Figure 2A The middle is T2 cells not transfected with HLA-A*1101, Figure 2B The middle is the T2 cells transfected with HLA-A*1101, and the transfection efficiency of HLA-A*1101 is 96.6%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a specific T cell receptor (TCR) aiming at EGFR L858R gene mutation and application of specific TCR. The TCR can combine with a new antigen peptide KITDFGRAK-HLA-A*1101 compoundderived from EGFR L858R gene mutation, and the TCR comprises the variable region and constant region of an alpha chain and a beta chain. T cells modified by the TCR has a specific killing effect on the HLA-A*1101 tumor cells of EGFR L858R gene mutation. In addition, the invention provides a pharmaceutical composition for treating tumor expressing the gene mutation, and the pharmaceutical composition is high in specificity and good in individual curative effect.

Description

technical field [0001] The invention relates to the field of genetic engineering and tumor immunotherapy, in particular to a specific T cell receptor for EGFR L858R gene mutation and its application. Background technique [0002] Tumor immunotherapy is a treatment method to control and eliminate tumors by restarting and maintaining the tumor-immune cycle and restoring the body's normal anti-tumor immune response. TCR (T cell receptor) therapy is T cell receptor therapy. In this therapy, endogenous T cells are isolated, engineered, and infused back into the human body. In this way, the number of T cells with the ability to target cancer cells will greatly increase. In addition to killing tumors quickly like cytotoxic chemotherapy and targeted therapy, this approach also avoids the delayed effects of vaccines and immune checkpoint inhibitor therapies. TCR-T is one of the most promising tumor treatment technologies following tumor surgery, radiotherapy, chemotherapy, and targ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/725C12N15/867C12N5/10A61K39/00A61P35/00
CPCA61K39/0011A61P35/00C07K14/7051C12N5/0636C12N15/86C12N2510/00C12N2740/15043
Inventor 杜学明李凤娥霍冲邓丽刚邹庆薇王亚玲
Owner 天津亨佳生物科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap